- ISIN
- US02043Q1076
- CUSIP
- 02043Q107
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- May 28, 2004
Highlights
- Market Cap
- $39.59B
- Enterprise Value
- $39.20B
- EPS (TTM)
- $4.26
- PE Ratio
- 67.18
- Total Revenue (TTM)
- $4.29B
- Gross Profit (TTM)
- $2.51B
- EBITDA (TTM)
- $729.86M
- Year Range
- $273.11 - $495.55
- Target Price
- $454.93
- ROA (TTM)
- 11.25%
- ROE (TTM)
- 53.68%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
ALNY Performance Chart
Alnylam Pharmaceuticals, Inc. (ALNY) is down 28.0% since the beginning of the year. At $286 per share, ALNY is trading 42.2% below its 52-week high of $496. Investors who bought $1,000 worth of ALNY shares 5 years ago would now be looking at an investment worth $1,640.
Loading charts...
Returns By Period
Alnylam Pharmaceuticals, Inc. (ALNY) has returned -27.97% so far this year and -7.52% over the past 12 months. Looking at the last ten years, ALNY has achieved an annualized return of 18.09%, outperforming the S&P 500 Index benchmark, which averaged 13.88% per year.
Alnylam Pharmaceuticals, Inc.
- 1D
- 2.99%
- 1M
- -3.71%
- YTD
- -27.97%
- 6M
- -29.75%
- 1Y
- -7.52%
- 3Y*
- 14.12%
- 5Y*
- 10.40%
- 10Y*
- 18.09%
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
ALNY Monthly Returns History
Based on dividend-adjusted daily data since Jun 1, 2004, ALNY's average daily return is +0.13%, while the average monthly return is +2.64%. At this rate, an investment would double in approximately 2.2 years.
Historically, 53% of months were positive and 47% were negative. The best month was Jun 2024 with a return of +63.7%, while the worst month was Oct 2016 at -47.5%. The longest winning streak lasted 8 consecutive months, and the longest losing streak was 8 months.
On a daily basis, ALNY closed higher 51% of trading days. The best single day was Jul 16, 2012 with a return of +53.0%, while the worst single day was Oct 6, 2016 at -48.5%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -14.99% | -1.52% | -0.62% | -6.46% | -2.43% | -5.16% | -27.97% | ||||||
| 2025 | 15.30% | -9.05% | 9.43% | -2.51% | 15.70% | 7.07% | 20.29% | 13.84% | 2.13% | 0.01% | -1.05% | -11.87% | 68.99% |
| 2024 | -9.67% | -12.62% | -1.09% | -3.68% | 3.11% | 63.71% | -2.28% | 10.62% | 4.70% | -3.07% | -5.07% | -7.02% | 22.94% |
| 2023 | -4.73% | -15.44% | 4.63% | -0.56% | -7.12% | 2.66% | 2.87% | 1.24% | -10.47% | -14.29% | 10.84% | 13.77% | -19.46% |
| 2022 | -18.86% | 14.72% | 3.45% | -18.29% | -5.72% | 15.94% | -2.61% | 45.50% | -3.15% | 3.55% | 6.43% | 7.73% | 40.14% |
| 2021 | 15.78% | -1.58% | -4.67% | -0.39% | 0.96% | 19.39% | 5.56% | 12.57% | -6.27% | -15.49% | 15.19% | -7.74% | 30.48% |
Benchmark Metrics
Alnylam Pharmaceuticals, Inc. has an annualized alpha of 24.62%, beta of 1.08, and R2 of 0.13 versus S&P 500 Index. Calculated based on daily prices since June 01, 2004.
- This stock captured 200.14% of S&P 500 Index gains and 139.38% of its losses - amplifying both gains and losses, but participating more in upside than downside.
- R2 of 0.13 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 24.62%
- Beta
- 1.08
- R²
- 0.13
- Upside Capture
- 200.14%
- Downside Capture
- 139.38%
Return for Risk
Risk / Return Rank
ALNY ranks 34 for risk / return — below 34% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Alnylam Pharmaceuticals, Inc. (ALNY) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ALNY | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.23 | ||
| Sortino ratioReturn per unit of downside risk | -2.80 | ||
| Omega ratioGain probability vs. loss probability | 1.00 | 1.37 | -0.37 |
| Calmar ratioReturn relative to maximum drawdown | -0.17 | 2.78 | -2.96 |
| Martin ratioReturn relative to average drawdown | -0.31 | 12.44 | -12.75 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Alnylam Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Alnylam Pharmaceuticals, Inc. was 83.58%, occurring on Oct 3, 2011. Recovery took 439 trading sessions.
The current Alnylam Pharmaceuticals, Inc. drawdown is 41.69%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2011 bear market2011 | -83.58%Oct 2011 | 3y 11mo | 1y 9mo | 5y 8moOct 2007 - Jul 2013 |
2016 bear market2016 | -77.36%Nov 2016 | 1y 4mo | 1y 7d | 2y 4moJun 2015 - Nov 2017 |
Rate-hike selloffLate 2018 | -57.81%Dec 2018 | 9mo 8d | 1y 5mo | 2y 3moMar 2018 - Jun 2020 |
2004 bear market2004 | -52.18%Aug 2004 | 2mo 7d | 4mo 23d | 7moJun 2004 - Jan 2005 |
2014 bear market2014 | -47.61%Apr 2014 | 3mo 14d | 5mo 29d | 9mo 13dJan 2014 - Oct 2014 |
Drawdown Indicators
| ALNY | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -83.58% | -56.78% | -26.80% |
Max Drawdown (1Y)Largest decline over 1 year | -43.39% | -9.10% | -34.29% |
Max Drawdown (3Y)Largest decline over 3 years | -43.39% | -18.90% | -24.49% |
Max Drawdown (5Y)Largest decline over 5 years | -43.39% | -25.43% | -17.96% |
Max Drawdown (10Y)Largest decline over 10 years | -59.95% | -33.92% | -26.03% |
Current DrawdownCurrent decline from peak | -41.69% | -1.80% | -39.89% |
Average DrawdownAverage peak-to-trough decline | -30.60% | -10.71% | -19.89% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 24.52% | 2.03% | +22.49% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Alnylam Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Alnylam Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for ALNY, comparing it with other companies in the Biotechnology industry. Currently, ALNY has a P/E ratio of 67.2. This P/E ratio is significantly higher than those of industry peers. This could indicate that the stock is overvalued or that investors expect strong future growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for ALNY relative to other companies in the Biotechnology industry. Currently, ALNY has a P/S ratio of 9.0. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for ALNY in comparison with other companies in the Biotechnology industry. Currently, ALNY has a P/B value of 36.8. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with ALNY
Add Alnylam Pharmaceuticals, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with ALNY